Subcutaneous injection of abelacimab results in lower levels of free factor XI and significantly fewer bleeding events than rivaroxaban in patients with atrial fibrillation at moderate-to-high risk ...

Researchers have found in a new research that among patients with atrial fibrillation who are at moderate-to-high risk for ...

Discover how abelacimab reduces bleeding risks in AFib patients by effectively lowering free factor XI levels.

Clinically significant reductions in bleeding underscore abelacimab’s strong potential to address an unmet need for patients ...

Abelacimab is a fully human monoclonal antibody that binds to the inactive form of factor XI and blocks its activation. The safety of abelacimab as compared with a direct oral anticoagulant in ...

Abelacimab, a factor XI inhibitor, demonstrated a 62–69% reduction in major bleeding compared to rivaroxaban in atrial fibrillation patients at moderate-to-high stroke risk, with comparable safety and ...

For people with atrial fibrillation (Afib), investigational abelacimab proved to be a potent dual factor XI/XIa inhibitor ...

Lower levels of free factor XI and fewer bleeding events seen in patients with atrial fibrillation at moderate-to-high risk for stroke. (HealthDay News) — Subcutaneous injection of abelacimab ...

The median reduction in free factor XI levels was 99% and 97% with abelacimab at a dose of 150mg and 90mg, respectively, at 3 months. (HealthDay News) — Subcutaneous injection of abelacimab ...